Phage T4 Nanoparticle-Based Intranasal Vaccine Provides Dual Protection Against COVID-19 and Influenza Through Rapid, Scalable Design

This study presents a bacteriophage T4-based nanoparticle platform that allows for the rapid design of a dual vaccine against COVID-19 and influenza. The vaccine, delivered intranasally, targets both SARS-CoV-2 and influenza with a multivalent approach using conserved antigens from both viruses. It induces strong systemic and mucosal immune responses in mice, providing complete protection against both viruses. The platform’s flexibility, scalability, and needle-free administration offer potential for future pandemic preparedness and vaccine distribution, particularly in resource-limited settings.

Full Article (https://www.biorxiv.org/content/10.1101/2024.10.09.617418v1)